ATE243531T1 - Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie - Google Patents

Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie

Info

Publication number
ATE243531T1
ATE243531T1 AT99119057T AT99119057T ATE243531T1 AT E243531 T1 ATE243531 T1 AT E243531T1 AT 99119057 T AT99119057 T AT 99119057T AT 99119057 T AT99119057 T AT 99119057T AT E243531 T1 ATE243531 T1 AT E243531T1
Authority
AT
Austria
Prior art keywords
magnesium
gene
administration
increase
gene therapy
Prior art date
Application number
AT99119057T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE243531T1 publication Critical patent/ATE243531T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99119057T 1998-09-30 1999-09-30 Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie ATE243531T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (de) 1998-09-30 1998-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie

Publications (1)

Publication Number Publication Date
ATE243531T1 true ATE243531T1 (de) 2003-07-15

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99119057T ATE243531T1 (de) 1998-09-30 1999-09-30 Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie

Country Status (10)

Country Link
US (2) US20020019357A1 (de)
EP (2) EP0998945A1 (de)
JP (1) JP5172054B2 (de)
AT (1) ATE243531T1 (de)
AU (1) AU767294B2 (de)
CA (1) CA2284399C (de)
DE (1) DE69909041T2 (de)
DK (1) DK1004320T3 (de)
ES (1) ES2201611T3 (de)
PT (1) PT1004320E (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080897A2 (en) * 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1249244A1 (de) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
EP1270733A1 (de) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Verfahren zum Einbringen von Nukleinsäure in eukaryotische Zellen
WO2004075924A1 (ja) * 2003-01-17 2004-09-10 Japan Genome Solutions, Inc. 遺伝子導入促進剤およびそれを含む遺伝子導入用組成物
ES2359473T3 (es) 2003-07-21 2011-05-23 Transgene S.A. Citoquinas multifuncionales.
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
WO2010105135A1 (en) * 2009-03-13 2010-09-16 Tufts University Methods, apparatuses, and kits for introducing genetic material into living cells
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
US20210205382A1 (en) * 2018-05-17 2021-07-08 University of Florida Research Foundation, Incorporation Methods and compositions for using metal elements in aav gene therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状ｄνａ導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
WO1999056784A2 (en) * 1998-05-06 1999-11-11 Transgene S.A. Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10

Also Published As

Publication number Publication date
AU767294B2 (en) 2003-11-06
DE69909041T2 (de) 2004-04-01
EP1004320B1 (de) 2003-06-25
DK1004320T3 (da) 2003-09-15
EP0998945A1 (de) 2000-05-10
US20020156045A1 (en) 2002-10-24
PT1004320E (pt) 2003-10-31
JP2000143549A (ja) 2000-05-23
JP5172054B2 (ja) 2013-03-27
US6881724B2 (en) 2005-04-19
AU5139799A (en) 2000-04-06
CA2284399A1 (en) 2000-03-30
EP1004320A1 (de) 2000-05-31
DE69909041D1 (de) 2003-07-31
CA2284399C (en) 2011-01-18
US20020019357A1 (en) 2002-02-14
ES2201611T3 (es) 2004-03-16

Similar Documents

Publication Publication Date Title
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
ATE200226T1 (de) Zusammensetzungen die verwendbar sind zur verabreichung von therapeutisch wirksamer polynukleotiden in eine zielzelle und ihre verwendung in gentherapie
DE69325256D1 (de) Insizierbare lecithin gel
AU687112B2 (en) Methods for increasing extracellular adenosine and for stabilization mast cells
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
EP0322319A3 (en) Composition comprising biodegradable ocular implants
ATE243531T1 (de) Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie
DE69426328D1 (de) Verwendung von mesothelialen zellen in der gentherapie
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
EP1153924A3 (de) Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften
ATE90345T1 (de) Bis-naphthalimide, ihre herstellung und verwendung.
ATA309588A (de) Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
ATE77750T1 (de) Antisaeurezusammensetzung.
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
ATE127842T1 (de) Megakaryocytopoietin, seine herstellung und benutzung.
EP0347932A3 (de) Behandlung von Zuständen, die eine erhöhte Sauerstoffverfügbarkeit im Gewebe von Säugern verlangen
DE3773716D1 (de) Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
ES2010282A6 (es) Procedimiento para reparar 8 -acilaminoergolina.
GR3006147T3 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1004320

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee